Anzeige
Mehr »
Donnerstag, 03.07.2025 - Börsentäglich über 12.000 News
Nach dem Genius Act: Dieses börsennotierte XRP-Unternehmen greift im Token-Finanzmarkt an!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
149 Leser
Artikel bewerten:
(0)

Global Pharmaceutical Functional and Multifunctional Excipients Industry to Cross the $10 Billion Mark by 2023

Innovative drug delivery technologies will impel market growth prospects, finds Frost & Sullivan

SANTA CLARA, California, Sept. 24, 2019 /PRNewswire/ -- Frost & Sullivan's latest analysis, Global Pharmaceutical Functional and Multifunctional Excipients Market, Forecast to 2023, reveals that the development of innovative drug delivery technologies, a growing generic and biosimilar drug market, and aging population are key factors increasing demand for functional and multifunctional excipients in the pharmaceutical industry. To succeed in a competitive global environment, excipient manufacturers should focus on developing innovative co-process and multifunctional excipients and replicate market leaders such as BASF, Ashland, Evonik, and Roquette by adopting strategies for partnerships and acquisitions to expand their customer base and global presence. Frost & Sullivan expects the market to increase at a steady compound annual growth rate (CAGR) of 5.5% and reach $10.5 billion by 2023.

"Demand for excipients is expected to increase due to different drug manufacturing types, continuous manufacturing processes, and new drug delivery technologies," said Prateeksha Kaul, Research Analyst, Chemicals, Materials & Nutrition, Frost & Sullivan. "As conventional excipients are not compatible with every process and technology, the need for modified and co-processed excipients is projected to increase."

For further information on this analysis, please click here: http://frost.ly/3ry

From a regional perspective, North America dominated the market with a share of 46.8% in 2018; Europe closely followed North America with a share of 23.2% in 2018. Asia-Pacific (APAC) is expected to witness a CAGR of 6.5% from 2018 to 2023.

"APAC has witnessed a significant economic boost in the last few years and will continue to produce the highest CAGR for the forecast period," observed Kaul. "With the increased production of generic drugs and biosimilars, and heightened awareness of improved treatment procedures, APAC's healthcare and pharmaceuticals industry outlook looks strong."

Excipient manufacturers can make the most of the prospects in the market by:

  • Developing excipients that are well-suited to continuous process technology, which has gained prominence in solid drug manufacturing.
  • Investing in co-processed excipients as they improve excipient quality and performance.
  • Developing and expanding parenteral-grade manufacturing of excipients due to long-term positive impacts and high demand.
  • Distributing generic drugs and related excipients in developing regions due to high demand, affordable price and patent expiry of branded drugs.

"Although there are significant opportunities in this sector, stringent regulatory processes, long development timelines, and high investment in R&D are some of the factors preventing manufacturers from developing novel excipients and could hinder market development," noted Kaul.

Frost & Sullivan's Analysis of the Global Pharmaceutical Functional and Multifunctional Excipients Market, Forecast to 2023 explores the factors and trends that have shaped the global excipients landscape, the challenges that lie ahead, and the opportunities that can be tapped. The market is segmented on the basis of chemical composition (organic and inorganic), functionality, routes of administration (oral, topical, parenteral and inhalation), and sources of origin (natural excipients and synthetic excipients).

Analysis of the Global Pharmaceutical Functional and Multifunctional Excipients Market, Forecast to 2023 is part of Frost & Sullivan's global Future of Chemicals in Personal Well-Being Growth Partnership Service program.

About Frost & Sullivan

For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Analysis of the Global Pharmaceutical Functional and Multifunctional Excipients Market, Forecast to 2023
K377_39

Contact:
Jacqui Holmes
E: jacqui.holmes@frost.com
http://ww2.frost.com

© 2019 PR Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.